The Covid Vaccine Windfall Turns on Pfizer and Moderna
Reduced demand and revenue for the jabs isn’t bad news. The industry is working as it’s designed.
The U.S. was in a fit of Covid panic during Thanksgiving week two years ago. The Omicron variant had emerged like a creature from the Black Lagoon. Public-health officials indicated we’d need another updated booster. Share prices in Pfizer and Moderna surged.